Alvotech (ALVO) Net Equity Issued and Repurchased (2023 - 2025)
Alvotech's (ALVO) quarterly Net Equity Issued and Repurchased came in at -$55.6 million in Q2 2025, down 548.06% on a YoY basis from $12.4 million in Q2 2024, and down 140.25% quarter-over-quarter from $138.0 million in Q1 2025.
Analysis
Alvotech (ALVO) Net Equity Issued and Repurchased (2023 - 2025) Analysis & Trends
Alvotech (ALVO) has reported Net Equity Issued and Repurchased for 3 consecutive years, with -$55.6 million the latest figure, recorded in Q2 2025.
- For the quarter ending Q2 2025, Net Equity Issued and Repurchased fell 548.06% year-over-year to -$55.6 million; the trailing twelve-month figure through Dec 2025 stood at $82.5 million (down 45.18% YoY), and the FY2025 full-year result was $82.5 million, down 45.18% from the prior year.
- Net Equity Issued and Repurchased slipped to -$55.6 million in Q2 2025 per ALVO's latest filing, from $138.0 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $138.0 million in Q1 2024 and bottomed at -$55.6 million in Q2 2025.
- Historically, Net Equity Issued and Repurchased has averaged $38.8 million across 3 years, with a median of $6.2 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased soared 620200.0% in 2024, then slumped 548.06% in 2025.
- Over 3 years, Net Equity Issued and Repurchased stood at $2000.0 in 2023, then surged by 620000.0% to $12.4 million in 2024, then plunged by 548.06% to -$55.6 million in 2025.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered -$55.6 million, $138.0 million, and $12.4 million for Q2 2025, Q1 2025, and Q2 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 700,000.00 |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | - |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | - |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | - |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -55.57 Mn |
| Mar 31, 2025 | 138.05 Mn |
| Jun 30, 2024 | 12.40 Mn |
| Mar 31, 2024 | 138.05 Mn |
| Dec 31, 2023 | 2,000.00 |
| Jun 30, 2023 | -2,000.00 |